Fig 1: Activation of InR-Akt-mTOR signaling by CG5399 overexpression requires cholesterol and clathrin-coated pits at the membrane.(A) Phospho-InR, phospho-Akt, and phospho-S6 in CG5399-overexpressing cells treated with methyl-beta-cyclodextrin (MβCD) at different concentrations. (B) Phospho-InR, phospho-Akt, and phospho-S6 in S2R+ cells with cholesterol supplementation. Two different cholesterol products from Sigma (C3045 for Lane 3 and C2044 for Lane 4) were used. (C) Phospho-Akt in CG5399-overexpressing cells following Flo1, Flo2, or Chc knockdown. Two nonoverlapping double-stranded RNAs (dsRNAs) targeting each gene were used. (D) Phospho-InR in CG5399-overexpressing cells following Chc knockdown. Two nonoverlapping dsRNAs targeting each gene were used. (E) Phospho-InR in S2R+ cells with cholesterol supplementation following clathrin heavy chain (Chc) knockdown. Two nonoverlapping dsRNAs targeting each gene were used. Figure 4—source data 1.Full source data for Figure 4.
Supplier Page from MilliporeSigma for Cholesterol